- Home
- LGCY vs ENTX Comparison
LGCY vs ENTX Comparison
Compare LGCY & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCY
- ENTX
- Stock Information
- Founded
- LGCY 2009
- ENTX 2010
- Country
- LGCY United States
- ENTX Israel
- Employees
- LGCY N/A
- ENTX N/A
- Industry
- LGCY
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LGCY
- ENTX Health Care
- Exchange
- LGCY NYSE
- ENTX Nasdaq
- Market Cap
- LGCY 67.3M
- ENTX 67.2M
- IPO Year
- LGCY 2024
- ENTX 2018
- Fundamental
- Price
- LGCY $5.77
- ENTX $1.73
- Analyst Decision
- LGCY Strong Buy
- ENTX Strong Buy
- Analyst Count
- LGCY 2
- ENTX 1
- Target Price
- LGCY $8.48
- ENTX $10.00
- AVG Volume (30 Days)
- LGCY 65.8K
- ENTX 127.7K
- Earning Date
- LGCY 11-14-2024
- ENTX 11-08-2024
- Dividend Yield
- LGCY N/A
- ENTX N/A
- EPS Growth
- LGCY 90.87
- ENTX N/A
- EPS
- LGCY 0.63
- ENTX N/A
- Revenue
- LGCY $49,638,473.00
- ENTX $99,000.00
- Revenue This Year
- LGCY N/A
- ENTX N/A
- Revenue Next Year
- LGCY N/A
- ENTX N/A
- P/E Ratio
- LGCY $10.34
- ENTX N/A
- Revenue Growth
- LGCY 32.36
- ENTX 607.14
- 52 Week Low
- LGCY $3.60
- ENTX $0.52
- 52 Week High
- LGCY $7.83
- ENTX $3.35
- Technical
- Relative Strength Index (RSI)
- LGCY N/A
- ENTX 44.32
- Support Level
- LGCY N/A
- ENTX $1.64
- Resistance Level
- LGCY N/A
- ENTX $1.80
- Average True Range (ATR)
- LGCY 0.00
- ENTX 0.09
- MACD
- LGCY 0.00
- ENTX -0.01
- Stochastic Oscillator
- LGCY 0.00
- ENTX 30.00
About LGCY LEGACY EDUCATION INC
Legacy Education Inc is engaged in career-focused, post-secondary education services to students at all stages of adult life, from recent high school graduates to working parents.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.